ABN AMRO Bank N.V. Has $189.80 Million Holdings in AbbVie Inc. $ABBV

ABN AMRO Bank N.V. trimmed its position in AbbVie Inc. (NYSE:ABBV) by 5.4% in the first quarter, according to its most recent filing with the SEC. The fund owned 864,389 shares of the company’s stock after selling 49,474 shares during the period. AbbVie accounts for approximately 2.0% of ABN AMRO Bank N.V.’s investment portfolio, making the stock its 17th biggest position. ABN AMRO Bank N.V.’s holdings in AbbVie were worth $189,798,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of ABBV. Bank of Jackson Hole Trust boosted its stake in shares of AbbVie by 0.6% during the fourth quarter. Bank of Jackson Hole Trust now owns 7,213 shares of the company’s stock valued at $1,648,000 after purchasing an additional 44 shares in the last quarter. Eclectic Associates Inc. ADV increased its stake in shares of AbbVie by 0.8% in the fourth quarter. Eclectic Associates Inc. ADV now owns 5,852 shares of the company’s stock valued at $1,337,000 after buying an additional 45 shares during the period. Imprint Wealth LLC raised its holdings in AbbVie by 56.2% in the 4th quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock valued at $29,000 after buying an additional 45 shares during the last quarter. Hardin Capital Partners LLC raised its holdings in AbbVie by 1.4% in the 4th quarter. Hardin Capital Partners LLC now owns 3,321 shares of the company’s stock valued at $759,000 after buying an additional 46 shares during the last quarter. Finally, Dogwood Wealth Management LLC boosted its position in AbbVie by 10.8% during the 4th quarter. Dogwood Wealth Management LLC now owns 473 shares of the company’s stock worth $108,000 after buying an additional 46 shares during the period. Institutional investors and hedge funds own 70.23% of the company’s stock.

AbbVie Stock Performance

NYSE:ABBV opened at $251.52 on Friday. The company has a market capitalization of $444.38 billion, a PE ratio of 123.90, a P/E/G ratio of 0.77 and a beta of 0.32. The company has a 50 day simple moving average of $215.16 and a two-hundred day simple moving average of $219.18. AbbVie Inc. has a fifty-two week low of $181.73 and a fifty-two week high of $253.35.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Wednesday, April 29th. The company reported $2.65 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.59 by $0.06. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. The firm had revenue of $15 billion for the quarter, compared to the consensus estimate of $14.72 billion. During the same quarter in the previous year, the company earned $2.46 EPS. The company’s revenue for the quarter was up 12.4% on a year-over-year basis. Research analysts predict that AbbVie Inc. will post 14.28 EPS for the current year.

AbbVie Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, August 14th. Investors of record on Wednesday, July 15th will be issued a $1.73 dividend. The ex-dividend date is Wednesday, July 15th. This represents a $6.92 annualized dividend and a yield of 2.8%. AbbVie’s payout ratio is presently 340.89%.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie said the FDA approved Skyrizi for pediatric use in psoriatic disease, making it the first and only IL-23 inhibitor in the U.S. approved for children six years and older weighing less than 40 kg with plaque psoriasis or psoriatic arthritis. The expansion broadens the drug’s addressable market and supports long-term sales growth. Article: SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease
• Positive Sentiment: AbbVie’s Apogee Therapeutics acquisition is being viewed favorably by analysts, with Canaccord raising its price target and saying the deal strengthens AbbVie’s long-term growth outlook by adding promising pipeline assets. Article: AbbVie Just Sparked a 46% Rally in Apogee. Here’s Why This $10.9 Billion Deal Could Be a Win for AbbVie Investors.
• Positive Sentiment: AbbVie is also benefiting from broader healthcare sector strength, with shares hitting new highs as investors rotate into defensive large-cap pharma names. Article: Lilly, J&J, AbbVie hit all-time highs as healthcare outperforms
• Neutral Sentiment: AbbVie announced it will host its second-quarter 2026 earnings call on July 31, which is a standard investor update and does not by itself change fundamentals. Article: AbbVie to Host Second-Quarter 2026 Earnings Conference Call
• Neutral Sentiment: Commentary pieces also highlighted AbbVie’s recent pediatric label expansions in Europe for Skyrizi and Maviret, reinforcing the company’s shift toward earlier-disease and younger-patient growth opportunities. Article: Will AbbVie’s (ABBV) Pediatric Expansions Reveal a Deeper Shift in Its Growth Mix?

Analyst Upgrades and Downgrades

ABBV has been the topic of a number of research reports. Piper Sandler reissued an “overweight” rating and set a $298.00 target price on shares of AbbVie in a report on Tuesday, June 23rd. Evercore set a $235.00 price target on shares of AbbVie in a report on Friday, May 15th. Wells Fargo & Company set a $260.00 price objective on shares of AbbVie in a research note on Monday, June 22nd. Bank of America upgraded AbbVie from a “neutral” rating to a “buy” rating and set a $234.00 price objective for the company in a report on Thursday, April 30th. Finally, BMO Capital Markets reaffirmed an “outperform” rating on shares of AbbVie in a research report on Monday, March 9th. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have issued a Hold rating to the company. According to MarketBeat, AbbVie has a consensus rating of “Moderate Buy” and a consensus target price of $253.81.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.